[8-K] Avanos Medical, Inc. Reports Material Event
Avanos Medical (AVNS) has filed an 8-K dated 5-Aug-25 that covers earnings disclosure, management changes and a product-line divestiture.
Item 2.02: The company furnished (not filed) a press release with results for Q2-25 and 1H-25 (Ex. 99.1); specific revenue, EPS and guidance figures are not included in this report.
Item 5.02 鈥� Leadership moves: Effective 1-Aug-25, CEO David Pacitti joined the Board, filling one vacancy. Scott Galovan (46), previously SVP-Strategy & Corp. Dev., was promoted to Senior VP & Chief Financial Officer. His package includes a $460k base salary, 70 % bonus target, a 2026 LTIP grant targeted at $1.6 m and an immediate $0.5 m time-based RSU award vesting 30 %/30 %/40 % over three years. Interim CFO Jason Pickett moves to Vice President, Corporate Finance & Treasurer.
Item 7.01 鈥� Strategic action: On 31-Jul-25 Avanos announced the divestiture of its Hyaluronic Acid product line to Channel-Markers Medical, LLC (Ex. 99.2). No purchase price or financial impact was disclosed in the filing.
Investors should review the attached exhibits for quantitative performance data and divestiture terms, as neither is detailed within the body of the 8-K.
Avanos Medical (AVNS) ha presentato un modulo 8-K datato 5-ago-25 che riguarda la divulgazione dei risultati finanziari, cambiamenti nella direzione e la cessione di una linea di prodotti.
Voce 2.02: La societ脿 ha fornito (ma non depositato) un comunicato stampa con i risultati del Q2-25 e del primo semestre 25 (Ex. 99.1); nel rapporto non sono inclusi dati specifici su ricavi, EPS e previsioni.
Voce 5.02 鈥� Cambiamenti nella leadership: A partire dal 1-ago-25, l鈥橝mministratore Delegato David Pacitti 猫 entrato nel Consiglio di Amministrazione, colmando una posizione vacante. Scott Galovan (46), precedentemente SVP-Strategia e Sviluppo Aziendale, 猫 stato promosso a Senior VP e Direttore Finanziario. Il suo pacchetto retributivo comprende uno stipendio base di 460.000 $, un bonus obiettivo del 70%, una concessione LTIP 2026 stimata a 1,6 milioni di dollari e un premio immediato in RSU basate sul tempo del valore di 0,5 milioni di dollari, con maturazione del 30%/30%/40% in tre anni. Il CFO ad interim Jason Pickett assume il ruolo di Vicepresidente, Finanza Aziendale e Tesoriere.
Voce 7.01 鈥� Azione strategica: Il 31-lug-25 Avanos ha annunciato la cessione della linea di prodotti all鈥橝cido Ialuronico a Channel-Markers Medical, LLC (Ex. 99.2). Nel deposito non sono stati rivelati n茅 il prezzo di acquisto n茅 l鈥檌mpatto finanziario.
Si consiglia agli investitori di consultare gli allegati per dati quantitativi sulle performance e termini della cessione, poich茅 nessuno dei due 猫 dettagliato nel corpo del modulo 8-K.
Avanos Medical (AVNS) ha presentado un formulario 8-K fechado el 5 de agosto de 2025 que incluye la divulgaci贸n de resultados financieros, cambios en la direcci贸n y la venta de una l铆nea de productos.
脥tem 2.02: La compa帽铆a proporcion贸 (pero no present贸) un comunicado de prensa con los resultados del segundo trimestre de 2025 y el primer semestre de 2025 (Ex. 99.1); este informe no incluye cifras espec铆ficas de ingresos, EPS ni previsiones.
脥tem 5.02 鈥� Cambios en el liderazgo: A partir del 1 de agosto de 2025, el CEO David Pacitti se uni贸 a la Junta Directiva, cubriendo una vacante. Scott Galovan (46), anteriormente SVP de Estrategia y Desarrollo Corporativo, fue promovido a Vicepresidente Senior y Director Financiero. Su paquete incluye un salario base de 460,000 $, un objetivo de bono del 70 %, una concesi贸n LTIP para 2026 valorada en 1.6 millones y una adjudicaci贸n inmediata de RSU basada en tiempo por 0.5 millones, con vesting del 30 %/30 %/40 % durante tres a帽os. El CFO interino Jason Pickett pas贸 a ser Vicepresidente de Finanzas Corporativas y Tesorero.
脥tem 7.01 鈥� Acci贸n estrat茅gica: El 31 de julio de 2025, Avanos anunci贸 la venta de su l铆nea de productos de 脕cido Hialur贸nico a Channel-Markers Medical, LLC (Ex. 99.2). No se revelaron el precio de compra ni el impacto financiero en la presentaci贸n.
Se recomienda a los inversores revisar los anexos adjuntos para obtener datos cuantitativos sobre el desempe帽o y los t茅rminos de la venta, ya que ninguno de los dos se detalla en el cuerpo del 8-K.
Avanos Medical(AVNS)電� 2025雲� 8鞗� 5鞚检瀽 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨溂氅�, 鞚� 氤搓碃靹滌棎電� 鞁れ爜 瓿店皽, 瓴届榿歆� 氤�瓴� 氚� 鞝滍拡 霛检澑 毵り皝 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
頃 2.02: 須岇偓電� 2025雲� 2攵勱赴 氚� 靸侂皹旮� 鞁れ爜鞐� 甏�頃� 氤措弰鞛愲(Ex. 99.1)毳� 鞝滉车頄堨溂雮�(鞝滌稖 鞎勲嫎) 鞚� 氤搓碃靹滌棎電� 甑泊鞝侅澑 毵れ稖, 欤茧嫻靾滌澊鞚�(EPS), 臧�鞚措崢鞀� 靾橃箻電� 韽暔霅橃 鞎婌晿鞀惦媹雼�.
頃 5.02 鈥� 毽崝鞁� 氤�瓴�: 2025雲� 8鞗� 1鞚茧秬搿� CEO David Pacitti臧� 鞚挫偓須岇棎 頃╇頃橃棳 瓿奠劃鞚� 毂勳洜鞀惦媹雼�. 鞚挫爠鞐� 鞝勲灥 氚� 旮办梾臧滊皽 靾橃劃 攵�靷灔鞚挫棃雿� Scott Galovan(46靹�)鞚� 靾橃劃 攵�靷灔 瓴� 斓滉碃鞛毂呾瀯鞛�(CFO)搿� 鞀轨頄堨姷雼堧嫟. 攴胳潣 氤挫儊 韺偆歆�鞐愲姅 鞐半磯 46毵� 雼煬, 70% 氤措剤鞀� 氇╉憸, 2026雲� 氇╉憸 160毵� 雼煬鞚� 鞛リ赴 鞚胳劶韹半笇 瓿勴殟(LTIP) 攵�鞐�, 攴鸽Μ瓿� 3雲勳棎 瓯胳硱 30%/30%/40%搿� 氩犾姢韺呺悩電� 50毵� 雼煬 靸侂嫻鞚� 鞁滉皠 旮半皹 鞝滍暅欤�(RSU) 歃夓嫓 靾橃棳臧� 韽暔霅╇媹雼�. 鞛勳嫓 CFO鞓�雿� Jason Pickett電� 旮办梾 鞛 氚� 鞛雼措嫻 攵�靷灔鞙茧 鞚措彊頄堨姷雼堧嫟.
頃 7.01 鈥� 鞝勲灥鞝� 臁办箻: 2025雲� 7鞗� 31鞚�, Avanos電� 頌堨晫耄靷� 鞝滍拡 霛检澑鞚� Channel-Markers Medical, LLC鞐� 毵り皝頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟(Ex. 99.2). 毵り皝 臧�瓴╈澊雮� 鞛 鞓來枼鞚� 氤搓碃靹滌棎 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
韴瀽鞛愲摛鞚� 鞝曤焿鞝� 靹标臣 雿办澊韯办檧 毵り皝 臁瓣贝鞚� 8-K 氤鸽鞐� 靸侅劯頌� 旮办灛霅橃柎 鞛堨 鞎婌溂氙�搿� 觳秬霅� 歃濍箼 鞛愲毳� 瓴�韱犿暊 瓴冹潉 甓岅碃頃╇媹雼�.
Avanos Medical (AVNS) a d茅pos茅 un formulaire 8-K dat茅 du 5 ao没t 2025 couvrant la divulgation des r茅sultats, des changements de direction et la cession d鈥檜ne gamme de produits.
Point 2.02 : La soci茅t茅 a fourni (mais pas d茅pos茅) un communiqu茅 de presse avec les r茅sultats du T2-25 et du premier semestre 2025 (Ex. 99.1) ; les chiffres sp茅cifiques de chiffre d鈥檃ffaires, BPA et pr茅visions ne sont pas inclus dans ce rapport.
Point 5.02 鈥� Changements de direction : 脌 compter du 1er ao没t 2025, le PDG David Pacitti a rejoint le conseil d鈥檃dministration, comblant un poste vacant. Scott Galovan (46 ans), auparavant SVP Strat茅gie et D茅veloppement Corporatif, a 茅t茅 promu Senior VP et Directeur Financier. Son package comprend un salaire de base de 460 000 $, un objectif de bonus de 70 %, une attribution LTIP 2026 cibl茅e 脿 1,6 million de dollars et une attribution imm茅diate de RSU bas茅es sur le temps d鈥檜ne valeur de 0,5 million, vestant 脿 30 %/30 %/40 % sur trois ans. Le CFO int茅rimaire Jason Pickett devient Vice-Pr茅sident, Finance d鈥橢ntreprise et Tr茅sorier.
Point 7.01 鈥� Action strat茅gique : Le 31 juillet 2025, Avanos a annonc茅 la cession de sa gamme de produits 脿 base d鈥檃cide hyaluronique 脿 Channel-Markers Medical, LLC (Ex. 99.2). Aucun prix d鈥檃chat ni impact financier n鈥檃 茅t茅 divulgu茅 dans le d茅p么t.
Les investisseurs sont invit茅s 脿 consulter les annexes jointes pour les donn茅es quantitatives de performance et les conditions de cession, car aucun d茅tail n鈥檈st fourni dans le corps du 8-K.
Avanos Medical (AVNS) hat am 5. August 2025 ein 8-K Formular eingereicht, das die Offenlegung der Ergebnisse, F眉hrungswechsel und den Verkauf einer Produktlinie umfasst.
Punkt 2.02: Das Unternehmen hat eine Pressemitteilung mit den Ergebnissen f眉r das 2. Quartal 2025 und das erste Halbjahr 2025 bereitgestellt (nicht eingereicht) (Ex. 99.1); spezifische Angaben zu Umsatz, Gewinn je Aktie und Prognosen sind in diesem Bericht nicht enthalten.
Punkt 5.02 鈥� F眉hrungswechsel: Zum 1. August 2025 trat CEO David Pacitti dem Vorstand bei und f眉llte eine Vakanz. Scott Galovan (46), zuvor Senior Vice President f眉r Strategie und Unternehmensentwicklung, wurde zum Senior Vice President und Chief Financial Officer bef枚rdert. Sein Verg眉tungspaket umfasst ein Grundgehalt von 460.000 $, ein Bonusziel von 70 %, eine LTIP-Zuteilung f眉r 2026 im Wert von 1,6 Mio. $ sowie eine sofortige zeitbasierte RSU-Zuteilung im Wert von 0,5 Mio. $, die 眉ber drei Jahre mit 30 %/30 %/40 % vestet. Der Interim-CFO Jason Pickett wechselte zum Vice President Corporate Finance & Treasurer.
Punkt 7.01 鈥� Strategische Ma脽nahme: Am 31. Juli 2025 k眉ndigte Avanos den Verkauf seiner Hyalurons盲ure-Produktlinie an Channel-Markers Medical, LLC an (Ex. 99.2). Kaufpreis und finanzielle Auswirkungen wurden im Bericht nicht offengelegt.
Investoren sollten die beigef眉gten Anlagen f眉r quantitative Leistungsdaten und Verkaufsbedingungen pr眉fen, da diese im Hauptteil des 8-K nicht n盲her erl盲utert werden.
- Permanent CFO appointment ends interim period, providing leadership stability for financial planning and reporting.
- Divestiture of non-core Hyaluronic Acid product line signals continued portfolio focus and potential capital generation.
- Board vacancy filled by CEO Pacitti, ensuring full board composition without expanding board size.
- No financial terms for the product-line sale were disclosed, limiting assessment of valuation and cash impact.
- Governance concentration: CEO now also serves as director, reducing independent oversight.
- CFO compensation increases fixed costs; long-term equity grants dilute shareholders albeit modestly.
Insights
TL;DR: Board seat for CEO and permanent CFO reduce leadership gap; strategic sale positive but terms undisclosed鈥攏et neutral impact.
Filling the board vacancy with the sitting CEO streamlines decision-making but also concentrates authority, a mixed governance signal. Naming a permanent CFO ends a four-month interim period and should stabilise financial reporting. Compensation appears market-comparable for a $1.0-1.2 bn market-cap med-tech firm. Lack of fresh external insights tempers enthusiasm. Overall, these changes modestly enhance leadership clarity without materially changing risk profile.
TL;DR: Divesting HA line sharpens focus on core portfolio; absent deal value, earnings effect can鈥檛 be gauged鈥攏eutral for now.
The Hyaluronic Acid franchise is peripheral to Avanos鈥� pain management and chronic care focus, so its sale could improve strategic coherence and margin mix. However, without disclosed proceeds or revenue contribution, investors cannot assess accretion, debt reduction, or capital redeployment potential. Management plans to discuss Q2 numbers separately (Ex. 99.1), leaving valuation impact contingent on forthcoming details.
Avanos Medical (AVNS) ha presentato un modulo 8-K datato 5-ago-25 che riguarda la divulgazione dei risultati finanziari, cambiamenti nella direzione e la cessione di una linea di prodotti.
Voce 2.02: La societ脿 ha fornito (ma non depositato) un comunicato stampa con i risultati del Q2-25 e del primo semestre 25 (Ex. 99.1); nel rapporto non sono inclusi dati specifici su ricavi, EPS e previsioni.
Voce 5.02 鈥� Cambiamenti nella leadership: A partire dal 1-ago-25, l鈥橝mministratore Delegato David Pacitti 猫 entrato nel Consiglio di Amministrazione, colmando una posizione vacante. Scott Galovan (46), precedentemente SVP-Strategia e Sviluppo Aziendale, 猫 stato promosso a Senior VP e Direttore Finanziario. Il suo pacchetto retributivo comprende uno stipendio base di 460.000 $, un bonus obiettivo del 70%, una concessione LTIP 2026 stimata a 1,6 milioni di dollari e un premio immediato in RSU basate sul tempo del valore di 0,5 milioni di dollari, con maturazione del 30%/30%/40% in tre anni. Il CFO ad interim Jason Pickett assume il ruolo di Vicepresidente, Finanza Aziendale e Tesoriere.
Voce 7.01 鈥� Azione strategica: Il 31-lug-25 Avanos ha annunciato la cessione della linea di prodotti all鈥橝cido Ialuronico a Channel-Markers Medical, LLC (Ex. 99.2). Nel deposito non sono stati rivelati n茅 il prezzo di acquisto n茅 l鈥檌mpatto finanziario.
Si consiglia agli investitori di consultare gli allegati per dati quantitativi sulle performance e termini della cessione, poich茅 nessuno dei due 猫 dettagliato nel corpo del modulo 8-K.
Avanos Medical (AVNS) ha presentado un formulario 8-K fechado el 5 de agosto de 2025 que incluye la divulgaci贸n de resultados financieros, cambios en la direcci贸n y la venta de una l铆nea de productos.
脥tem 2.02: La compa帽铆a proporcion贸 (pero no present贸) un comunicado de prensa con los resultados del segundo trimestre de 2025 y el primer semestre de 2025 (Ex. 99.1); este informe no incluye cifras espec铆ficas de ingresos, EPS ni previsiones.
脥tem 5.02 鈥� Cambios en el liderazgo: A partir del 1 de agosto de 2025, el CEO David Pacitti se uni贸 a la Junta Directiva, cubriendo una vacante. Scott Galovan (46), anteriormente SVP de Estrategia y Desarrollo Corporativo, fue promovido a Vicepresidente Senior y Director Financiero. Su paquete incluye un salario base de 460,000 $, un objetivo de bono del 70 %, una concesi贸n LTIP para 2026 valorada en 1.6 millones y una adjudicaci贸n inmediata de RSU basada en tiempo por 0.5 millones, con vesting del 30 %/30 %/40 % durante tres a帽os. El CFO interino Jason Pickett pas贸 a ser Vicepresidente de Finanzas Corporativas y Tesorero.
脥tem 7.01 鈥� Acci贸n estrat茅gica: El 31 de julio de 2025, Avanos anunci贸 la venta de su l铆nea de productos de 脕cido Hialur贸nico a Channel-Markers Medical, LLC (Ex. 99.2). No se revelaron el precio de compra ni el impacto financiero en la presentaci贸n.
Se recomienda a los inversores revisar los anexos adjuntos para obtener datos cuantitativos sobre el desempe帽o y los t茅rminos de la venta, ya que ninguno de los dos se detalla en el cuerpo del 8-K.
Avanos Medical(AVNS)電� 2025雲� 8鞗� 5鞚检瀽 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨溂氅�, 鞚� 氤搓碃靹滌棎電� 鞁れ爜 瓿店皽, 瓴届榿歆� 氤�瓴� 氚� 鞝滍拡 霛检澑 毵り皝 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
頃 2.02: 須岇偓電� 2025雲� 2攵勱赴 氚� 靸侂皹旮� 鞁れ爜鞐� 甏�頃� 氤措弰鞛愲(Ex. 99.1)毳� 鞝滉车頄堨溂雮�(鞝滌稖 鞎勲嫎) 鞚� 氤搓碃靹滌棎電� 甑泊鞝侅澑 毵れ稖, 欤茧嫻靾滌澊鞚�(EPS), 臧�鞚措崢鞀� 靾橃箻電� 韽暔霅橃 鞎婌晿鞀惦媹雼�.
頃 5.02 鈥� 毽崝鞁� 氤�瓴�: 2025雲� 8鞗� 1鞚茧秬搿� CEO David Pacitti臧� 鞚挫偓須岇棎 頃╇頃橃棳 瓿奠劃鞚� 毂勳洜鞀惦媹雼�. 鞚挫爠鞐� 鞝勲灥 氚� 旮办梾臧滊皽 靾橃劃 攵�靷灔鞚挫棃雿� Scott Galovan(46靹�)鞚� 靾橃劃 攵�靷灔 瓴� 斓滉碃鞛毂呾瀯鞛�(CFO)搿� 鞀轨頄堨姷雼堧嫟. 攴胳潣 氤挫儊 韺偆歆�鞐愲姅 鞐半磯 46毵� 雼煬, 70% 氤措剤鞀� 氇╉憸, 2026雲� 氇╉憸 160毵� 雼煬鞚� 鞛リ赴 鞚胳劶韹半笇 瓿勴殟(LTIP) 攵�鞐�, 攴鸽Μ瓿� 3雲勳棎 瓯胳硱 30%/30%/40%搿� 氩犾姢韺呺悩電� 50毵� 雼煬 靸侂嫻鞚� 鞁滉皠 旮半皹 鞝滍暅欤�(RSU) 歃夓嫓 靾橃棳臧� 韽暔霅╇媹雼�. 鞛勳嫓 CFO鞓�雿� Jason Pickett電� 旮办梾 鞛 氚� 鞛雼措嫻 攵�靷灔鞙茧 鞚措彊頄堨姷雼堧嫟.
頃 7.01 鈥� 鞝勲灥鞝� 臁办箻: 2025雲� 7鞗� 31鞚�, Avanos電� 頌堨晫耄靷� 鞝滍拡 霛检澑鞚� Channel-Markers Medical, LLC鞐� 毵り皝頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟(Ex. 99.2). 毵り皝 臧�瓴╈澊雮� 鞛 鞓來枼鞚� 氤搓碃靹滌棎 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
韴瀽鞛愲摛鞚� 鞝曤焿鞝� 靹标臣 雿办澊韯办檧 毵り皝 臁瓣贝鞚� 8-K 氤鸽鞐� 靸侅劯頌� 旮办灛霅橃柎 鞛堨 鞎婌溂氙�搿� 觳秬霅� 歃濍箼 鞛愲毳� 瓴�韱犿暊 瓴冹潉 甓岅碃頃╇媹雼�.
Avanos Medical (AVNS) a d茅pos茅 un formulaire 8-K dat茅 du 5 ao没t 2025 couvrant la divulgation des r茅sultats, des changements de direction et la cession d鈥檜ne gamme de produits.
Point 2.02 : La soci茅t茅 a fourni (mais pas d茅pos茅) un communiqu茅 de presse avec les r茅sultats du T2-25 et du premier semestre 2025 (Ex. 99.1) ; les chiffres sp茅cifiques de chiffre d鈥檃ffaires, BPA et pr茅visions ne sont pas inclus dans ce rapport.
Point 5.02 鈥� Changements de direction : 脌 compter du 1er ao没t 2025, le PDG David Pacitti a rejoint le conseil d鈥檃dministration, comblant un poste vacant. Scott Galovan (46 ans), auparavant SVP Strat茅gie et D茅veloppement Corporatif, a 茅t茅 promu Senior VP et Directeur Financier. Son package comprend un salaire de base de 460 000 $, un objectif de bonus de 70 %, une attribution LTIP 2026 cibl茅e 脿 1,6 million de dollars et une attribution imm茅diate de RSU bas茅es sur le temps d鈥檜ne valeur de 0,5 million, vestant 脿 30 %/30 %/40 % sur trois ans. Le CFO int茅rimaire Jason Pickett devient Vice-Pr茅sident, Finance d鈥橢ntreprise et Tr茅sorier.
Point 7.01 鈥� Action strat茅gique : Le 31 juillet 2025, Avanos a annonc茅 la cession de sa gamme de produits 脿 base d鈥檃cide hyaluronique 脿 Channel-Markers Medical, LLC (Ex. 99.2). Aucun prix d鈥檃chat ni impact financier n鈥檃 茅t茅 divulgu茅 dans le d茅p么t.
Les investisseurs sont invit茅s 脿 consulter les annexes jointes pour les donn茅es quantitatives de performance et les conditions de cession, car aucun d茅tail n鈥檈st fourni dans le corps du 8-K.
Avanos Medical (AVNS) hat am 5. August 2025 ein 8-K Formular eingereicht, das die Offenlegung der Ergebnisse, F眉hrungswechsel und den Verkauf einer Produktlinie umfasst.
Punkt 2.02: Das Unternehmen hat eine Pressemitteilung mit den Ergebnissen f眉r das 2. Quartal 2025 und das erste Halbjahr 2025 bereitgestellt (nicht eingereicht) (Ex. 99.1); spezifische Angaben zu Umsatz, Gewinn je Aktie und Prognosen sind in diesem Bericht nicht enthalten.
Punkt 5.02 鈥� F眉hrungswechsel: Zum 1. August 2025 trat CEO David Pacitti dem Vorstand bei und f眉llte eine Vakanz. Scott Galovan (46), zuvor Senior Vice President f眉r Strategie und Unternehmensentwicklung, wurde zum Senior Vice President und Chief Financial Officer bef枚rdert. Sein Verg眉tungspaket umfasst ein Grundgehalt von 460.000 $, ein Bonusziel von 70 %, eine LTIP-Zuteilung f眉r 2026 im Wert von 1,6 Mio. $ sowie eine sofortige zeitbasierte RSU-Zuteilung im Wert von 0,5 Mio. $, die 眉ber drei Jahre mit 30 %/30 %/40 % vestet. Der Interim-CFO Jason Pickett wechselte zum Vice President Corporate Finance & Treasurer.
Punkt 7.01 鈥� Strategische Ma脽nahme: Am 31. Juli 2025 k眉ndigte Avanos den Verkauf seiner Hyalurons盲ure-Produktlinie an Channel-Markers Medical, LLC an (Ex. 99.2). Kaufpreis und finanzielle Auswirkungen wurden im Bericht nicht offengelegt.
Investoren sollten die beigef眉gten Anlagen f眉r quantitative Leistungsdaten und Verkaufsbedingungen pr眉fen, da diese im Hauptteil des 8-K nicht n盲her erl盲utert werden.
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||||||||
| (Address of principal executive offices) | (Zip code) | |||||||||||||||||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||
| Exhibit No. | Description | |||||||
99.1 | Press release issued by Avanos Medical, Inc. on August 5, 2025 | |||||||
99.2 | Press release issued by Avanos Medical, Inc. on July 31, 2025 | |||||||
99.3 | Press release issued by Avanos Medical Inc., on August 5, 2025 | |||||||
10.1* | Offer Letter by and between Avanos Medical, Inc. and Scott Galovan | |||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |||||||
| AVANOS MEDICAL, INC. | ||||||||||||||
| Date: | August 5, 2025 | By: | /s/ Mojirade James | |||||||||||
| Mojirade James Senior Vice President and General Counsel | ||||||||||||||
Source:
FAQ
Why did Avanos Medical (AVNS) file this 8-K on 5-Aug-25?
Who is the new Chief Financial Officer of AVNS?
What compensation will the new CFO receive?
What product line did Avanos divest in July 2025?
Does the filing include Avanos鈥� Q2-25 financial results?
Is there information on the sale price of the HA product line?
